News | 27 February 2026
Novo Nordisk & Vivtex team up to revolutionize oral hiologics
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
Asahi Kasei Pharma receives worldwide exclusive rights for the research, development, manufacturing, and marketing of the active ingredients
Zydus has developed an innovative Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a patient-friendly reusable pen for which the company has exclusive rights
For the fourth quarter, revenue surged 47% year-on-year to Rs. 2,510 million, driven by a 23% rise in domestic sales and a 9.3x jump in export sales
The new solution combines Watchmaker Genomics’ high-performance NGS chemistry with Volta’s digital fluidics platform
The new patents cover critical advancements in cochlear implant technology
Asahi Kasei is consistently pursuing its strategy of building a focused, sustainable specialty pharmaceutical platform for immunocompromised and medically complex patient groups
New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform
The innovative eyedrop targets inflammation and pain following ocular surgery
The announcement follows a record-setting $1.2 million accelerated LineaDNA order
NCFB is a chronic lung condition where damaged airways cause persistent coughing and mucus production
Brivaracetam is the bioequivalent to Briviact Oral Solution, 10 mg/mL, of UCB
Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management
Under the deal, Quiver will receive an undisclosed advance payment and research support
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
The collaboration merges biomodal’s 5-base and 6-base sequencing solutions, duet +modC and duet evoC
One of India’s top integrated contract research, development, and manufacturing organizations (CRDMOs) is on a hiring spree
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
Subscribe To Our Newsletter & Stay Updated
